Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson innovative Medicine Segment Total — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q3 2026
16,757
Period ended Sep 30, 2026
Change on a year earlier
+7.7%
15,563 in Q3 2025
History
43 quarters
Since Q1 2016
Sources
24
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Innovative Medicine Segment Total — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 16,757 | +7.7% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2026 | Jun 28, 2026 | 16,384 | +7.8% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2026 | Mar 29, 2026 | 15,426 | +11.2% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2025 | Dec 28, 2025 | 15,763 | +10.0% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2025 | Sep 28, 2025 | 15,563 | +6.7% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2025 | Jun 29, 2025 | 15,202 | +4.9% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2025 | Mar 30, 2025 | 13,873 | +2.3% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2024 | Dec 29, 2024 | 14,332 | +4.4% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2024 | Sep 29, 2024 | 14,580 | +4.9% | Form 10-Q (filed 2025-10-22) ↗ |
| Q2 2024 | Jun 30, 2024 | 14,490 | +5.5% | Form 10-Q (filed 2025-07-24) ↗ |
| Q1 2024 | Mar 31, 2024 | 13,562 | +1.1% | Form 10-Q (filed 2025-04-23) ↗ |
| Q4 2023 | Dec 31, 2023 | 13,722 | +4.2% | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2023 | Oct 1, 2023 | 13,893 | +5.1% | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2023 | Jul 2, 2023 | 13,731 | +3.1% | Form 10-Q (filed 2024-07-25) ↗ |
| Q1 2023 | Apr 2, 2023 | 13,413 | +4.2% | Form 10-Q (filed 2024-05-01) ↗ |
| Q4 2022 | Jan 1, 2023 | 13,163 | -7.4% | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2022 | Oct 2, 2022 | 13,214 | +2.6% | Form 10-K (filed 2024-02-16) ↗ |
| Q2 2022 | Jul 3, 2022 | 13,317 | +6.7% | Form 10-K (filed 2024-02-16) ↗ |
| Q1 2022 | Apr 3, 2022 | 12,869 | +6.3% | Form 10-K (filed 2024-02-16) ↗ |
| Q4 2021 | Jan 2, 2022 | 14,217 | +19.8% | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 12,882 | +12.8% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2021 | Jul 4, 2021 | 12,480 | +16.1% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 12,101 | +8.7% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Jan 3, 2021 | 11,871 | +12.5% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2020 | Sep 27, 2020 | 11,418 | +5.0% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2020 | Jun 28, 2020 | 10,752 | +2.1% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2020 | Mar 29, 2020 | 11,134 | +8.7% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 29, 2019 | 10,548 | +3.5% | Form 10-K (filed 2020-02-18) ↗ |
| Q3 2019 | Sep 29, 2019 | 10,877 | +5.1% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2019 | Jun 30, 2019 | 10,529 | +1.7% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2019 | Mar 31, 2019 | 10,244 | +4.1% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 10,190 | +5.3% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2018 | Sep 30, 2018 | 10,346 | +6.7% | Form 10-K (filed 2019-02-20) ↗ |
| Q2 2018 | Jul 1, 2018 | 10,354 | +19.9% | Form 10-K (filed 2019-02-20) ↗ |
| Q1 2018 | Apr 1, 2018 | 9,844 | +19.4% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 9,681 | +17.6% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2017 | Oct 1, 2017 | 9,695 | +15.4% | Form 10-K (filed 2019-02-20) ↗ |
| Q2 2017 | Jul 2, 2017 | 8,635 | -0.2% | Form 10-K (filed 2019-02-20) ↗ |
| Q1 2017 | Apr 2, 2017 | 8,245 | +0.8% | Form 10-K (filed 2019-02-20) ↗ |
| Q4 2016 | Jan 1, 2017 | 8,232 | – | Form 10-K (filed 2018-02-21) ↗ |
| Q3 2016 | Oct 2, 2016 | 8,400 | – | Form 10-K (filed 2018-02-21) ↗ |
| Q2 2016 | Jul 3, 2016 | 8,654 | – | Form 10-K (filed 2018-02-21) ↗ |
| Q1 2016 | Apr 3, 2016 | 8,178 | – | Form 10-K (filed 2018-02-21) ↗ |
Breakdown
What makes up innovative medicine segment total — worldwide sales ($m)
- Innovative Medicine Segment Total — U.S. sales ($M)10,447 · Q3 2026
- Innovative Medicine Segment Total — International sales ($M)6,310 · Q3 2026
- Innovative Medicine Segment Total — Worldwide reported growth YoY (%)7.7% · Q3 2026
- Innovative Medicine Segment Total — Worldwide operational (constant-currency) growth YoY (%)7.9% · Q3 2026
- Innovative Medicine — Worldwide adjusted operational growth ex-A&D YoY (%)8.0% · Q3 2026
- Oncology Therapeutic Area Total — Worldwide sales ($M)7,602 · Q3 2026
- Immunology Therapeutic Area Total — Worldwide sales ($M)4,221 · Q3 2026
Cite this data
StockData. (2026). Johnson & Johnson Innovative Medicine Segment Total — Worldwide sales ($M) ($M), quarterly Q1 2016–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/seg_innovative_med
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.